Biogen stock holds firm as earnings and analyst calls support it
Published on 08/22/2026 at 12:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Biogen Inc. (US09062X1037) opened at $216.78 on Friday, while the latest analyst snapshot shows a $32.03 billion market cap and a 52-week range of $131.52 to $222.15. The stock is also trading above its 200-day moving average of $194.48 and below the recent high of $222.15.
Earnings set the tone
The company reported $3.60 in diluted EPS on July 29, 2026, above the $2.94 consensus estimate by $0.66, on revenue of $2.74 billion versus $2.46 billion expected. Revenue rose 3.4 percent from the same quarter a year earlier, and the company set FY 2026 guidance at $12.00 to $13.00 EPS.
That mix matters because the latest update paired a revenue beat with a clear full-year earnings range, giving investors two concrete reference points instead of one. The current analyst backdrop remains constructive, with an average target of $227.07 and a Moderate Buy stance across the Street snapshot.
Shareholders keep adding
Fresh filing coverage on August 22, 2026 showed new positions from Allworth Financial LP and Great Lakes Advisors LLC, with stakes valued at $1.74 million and $2.05 million, respectively. The same coverage put institutional ownership at 87.93 percent, underscoring how heavily the stock is already held by large investors.
The comparison that stands out is simple: Biogen's July 29 earnings beat came with a $0.66 EPS margin to estimates, while the stock still trades $5.37 below its 52-week high of $222.15. That leaves the shares priced between strong recent operating results and a market that has not fully pushed them back to the peak.
Multiple sclerosis still matters
Biogen's marketed portfolio still includes long-running neurology franchises such as Avonex, Tysabri and Tecfidera, products that keep the company's revenue base tied to the broader neuroscience market. The July 29 quarter also showed a return on equity of 11.18 percent and a net margin of 8.32 percent, both figures that help frame the quality of the profit recovery.
Biogen shares now
Biogen shares opened at $216.78 on August 22, 2026, leaving the stock within 2.4 percent of its 52-week high of $222.15. The next reported earnings date was not included in the source set used here.
Fact box
Company: Biogen Inc.
ISIN: US09062X1037
Ticker: BIIB
Exchange: Nasdaq
Price (as of August 22, 2026): $216.78 USD
Market cap: $32.03 billion
Sector / Industry: Health Care / Biotechnology
Index membership: Nasdaq-100
